Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAT4 Gel in Healthy Volunteers
NCT02647853Phase 1Completed
- Sponsor
- Topokine Therapeutics
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tafluprost in nasolabial folds, lipoatrophy and lipodystrophy (3 arms), sponsored by Topokine Therapeutics. Primary endpoint: Adverse Event rates at 21 days. Started Oct 2014; status: completed.
02
Drugs
tafluprost
03
Conditions
nasolabial foldslipoatrophylipodystrophy
Beyond the preview
Go deeper on NCT02647853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647853.